NO20075723L - Tiazolforbindelser og fremgangsmater for anvendelse - Google Patents
Tiazolforbindelser og fremgangsmater for anvendelseInfo
- Publication number
- NO20075723L NO20075723L NO20075723A NO20075723A NO20075723L NO 20075723 L NO20075723 L NO 20075723L NO 20075723 A NO20075723 A NO 20075723A NO 20075723 A NO20075723 A NO 20075723A NO 20075723 L NO20075723 L NO 20075723L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- methods
- compound
- administering
- Prior art date
Links
- 150000003557 thiazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 208000035473 Communicable disease Diseases 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67913305P | 2005-05-09 | 2005-05-09 | |
| PCT/US2006/017692 WO2006122011A2 (fr) | 2005-05-09 | 2006-05-09 | Composes thiazole et procedes d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075723L true NO20075723L (no) | 2008-02-05 |
Family
ID=36968742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075723A NO20075723L (no) | 2005-05-09 | 2007-11-09 | Tiazolforbindelser og fremgangsmater for anvendelse |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8088806B2 (fr) |
| EP (1) | EP1879575A2 (fr) |
| JP (1) | JP2008540537A (fr) |
| KR (1) | KR20080019213A (fr) |
| CN (1) | CN101247807A (fr) |
| AP (1) | AP2358A (fr) |
| AU (1) | AU2006244203B2 (fr) |
| BR (1) | BRPI0608910A2 (fr) |
| CA (1) | CA2607617A1 (fr) |
| EA (1) | EA200702445A1 (fr) |
| IL (1) | IL186970A0 (fr) |
| MX (1) | MX2007013955A (fr) |
| NO (1) | NO20075723L (fr) |
| NZ (1) | NZ563866A (fr) |
| SG (1) | SG159561A1 (fr) |
| UA (1) | UA92746C2 (fr) |
| WO (1) | WO2006122011A2 (fr) |
| ZA (1) | ZA200709751B (fr) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007019417A1 (fr) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Dérivés d’oxazolopyridine comme modulateurs du sirtuin |
| JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
| CN101426774B (zh) | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
| BRPI0714793A2 (pt) | 2006-08-03 | 2015-06-16 | Tufts College | Análogos de niacina não enrubecedores e método de uso dos mesmos. |
| BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| MX2009003080A (es) | 2006-09-22 | 2009-04-02 | Novartis Ag | Compuestos organicos heterociclicos. |
| TW200831084A (en) * | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
| JP2010513403A (ja) | 2006-12-20 | 2010-04-30 | ノバルティス アーゲー | Ｓｃｄ阻害剤としての２−置換５員ヘテロ環 |
| US7985763B2 (en) | 2007-04-10 | 2011-07-26 | National Health Research Institutes | Hepatitis C virus inhibitors |
| US20100120784A1 (en) * | 2007-04-20 | 2010-05-13 | Lachance Nicolas | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008147557A2 (fr) * | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Thiazoles à substitution hétéroaryle |
| WO2008141455A1 (fr) * | 2007-05-23 | 2008-11-27 | Merck Frosst Canada Ltd. | Composés hétéroaromatiques bicycliques utilisés en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
| US7897764B2 (en) | 2007-06-08 | 2011-03-01 | National Health Research Institutes | Thiourea derivatives |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| EP2181110A2 (fr) * | 2007-07-13 | 2010-05-05 | ADDEX Pharma S.A. | Nouveaux dérivés hétéroaromatiques et leur utilisation en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate |
| GB2455111A (en) * | 2007-11-28 | 2009-06-03 | Addex Pharmaceuticals Sa | Metabotropic glutamate receptor (mGluR4) modulators having 5- or 6-membered N-heteroaryl ring substituted by both N-cyclylamino & 5-membered N-heteroaryl ring |
| CN101801942B (zh) | 2007-07-17 | 2013-03-27 | 美国艾森生物科学公司 | 杂环化合物和作为抗癌剂的用途 |
| WO2009012573A1 (fr) * | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd. | Composés hétéroaromatiques bicycliques en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
| JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
| EA019357B1 (ru) | 2007-08-03 | 2014-03-31 | Ромарк Лабораториз Л.С. | Алкилсульфонилзамещённые n-(тиазол-2-ил)бензамиды и их применение для лечения вирусной инфекции гепатита c |
| HRP20120948T1 (hr) * | 2007-10-09 | 2012-12-31 | Merck Patent Gmbh | Derivati piridina koji su korisni kao aktivatori glukokinaze |
| WO2009051909A1 (fr) * | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Composés présentant une activité de correction du traitement cellulaire cftr mutante, et utilisations de ceux-ci |
| CA2703106C (fr) | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Derives d'azolecarboxamide comme inhibiteurs de trka |
| EP2070925A1 (fr) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés de 2-thiazol-4-amides d'acide carboxylique substitués, leur fabrication et leur utilisation en tant que médicament |
| EP2070924A1 (fr) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament |
| EP2070916A1 (fr) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés de 2-aryl-thiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament |
| TWI361808B (en) | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
| EP2101173A1 (fr) | 2008-03-14 | 2009-09-16 | Vivalis | Procédé in vitro pour déterminer si un candidat destiné à un médicament pour une protéine cible est actif contre une variante de cette protéine |
| US8198284B2 (en) | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
| US8106209B2 (en) * | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| WO2010008831A2 (fr) * | 2008-06-24 | 2010-01-21 | Irm Llc | Composés et procédés pour moduler les récepteurs couplés à la protéine g |
| EP3111956B1 (fr) * | 2008-07-01 | 2019-05-08 | PTC Therapeutics, Inc. | Modulateurs de l'expression de la protéine bmi1 |
| WO2010009139A2 (fr) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Composés inhibiteurs de pyrimidine imidazolyle |
| WO2010009166A1 (fr) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Composés inhibiteurs de l’oxindolyle |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| NZ590747A (en) | 2008-07-28 | 2012-11-30 | Gilead Sciences Inc | Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds |
| BRPI0917013A2 (pt) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto |
| EP2324025A1 (fr) | 2008-08-11 | 2011-05-25 | Smithkline Beecham Corporation | Dérivés purines destinés à être utilisés dans le traitement de maladies allergiques, inflammatoires et infectieuses |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| AU2009283195A1 (en) * | 2008-08-18 | 2010-02-25 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| GB0900388D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds |
| WO2010132404A1 (fr) | 2009-05-12 | 2010-11-18 | Romark Laboratories L.C. | Composés haloalkyl hétéroaryl benzamide |
| MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
| NZ596863A (en) | 2009-06-08 | 2014-02-28 | Gilead Sciences Inc | Alkanoylamino benzamide aniline hdac inhibitor compounds |
| CN101928283A (zh) * | 2009-06-25 | 2010-12-29 | 上海唐润医药科技有限公司 | 具有抗hcv活性的化合物及其用途 |
| CA3038405C (fr) | 2009-06-26 | 2022-02-01 | Romark Laboratories L.C. | Composes et procedes pour traiter la grippe |
| JP5922587B2 (ja) | 2010-02-10 | 2016-05-24 | グラクソスミスクライン エルエルシー | ６−アミノ−２−｛［（１ｓ）−１−メチルブチル］オキシ｝−９−［５−（１−ピペリジニル）ペンチル］−７，９−ジヒドロ−８ｈ−プリン−８−オンマレイン酸塩 |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| RU2012140020A (ru) * | 2010-02-19 | 2014-03-27 | Ацея Байосайенсиз Инк. | Гетероциклические соединения и их применение в качестве противораковых средств |
| CN105906617B (zh) | 2010-03-17 | 2018-09-04 | 泰纬生命科技股份有限公司 | Hec1活性调节剂及其方法 |
| WO2012037349A2 (fr) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Composés |
| WO2012037351A1 (fr) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Composés |
| WO2012075393A2 (fr) * | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
| US8835456B1 (en) | 2011-03-18 | 2014-09-16 | Achillion Pharmaceuticals, Inc. | NS5A inhibitors useful for treating HCV |
| CN103097367B (zh) * | 2011-04-02 | 2014-12-03 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯丙酸化合物、其制备方法及其医药用途 |
| MX349079B (es) | 2011-05-27 | 2017-07-07 | Achillion Pharmaceuticals Inc | Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc. |
| WO2013033037A2 (fr) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Nouveaux composés d'antiprion |
| BR112014007599A2 (pt) * | 2011-09-30 | 2017-04-11 | Kineta Inc | compostos anti-virais |
| CA2850779A1 (fr) * | 2011-10-04 | 2013-04-11 | Institute For Hepatitis And Virus Research | Aminothiazoles substitues en tant qu'inhibiteurs de cancers, notamment le carcinome hepatocellulaire, et en tant qu'inhibiteurs de la replication du virus de l'hepatite |
| US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| CN104080452A (zh) | 2011-10-26 | 2014-10-01 | 美国政府健康及人类服务部 | 用小分子chk2抑制剂治疗hcv感染的方法 |
| US11071736B2 (en) | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
| EP2869897A4 (fr) | 2012-07-06 | 2016-09-28 | Univ Duke | Activation du canal ionique trpv4 par stimuli physiques et rôle critique de trpv4 dans l'inflammation et la démangeaison spécifique à un organe |
| MX2015001793A (es) * | 2012-08-09 | 2015-05-07 | Neuropore Therapies Inc | Derivados de benceno sustituidos con arilo y heteroarilo como moduladores de las trayectorias de señalizacion de cinasa pi3. |
| US9951055B2 (en) | 2012-10-19 | 2018-04-24 | Massachusetts Institute Of Technology | Thiazole-based inhibitors of scavenger receptor BI |
| WO2014063168A1 (fr) | 2012-10-19 | 2014-04-24 | The Broad Institute, Inc. | Inhibiteurs hétérocycle - bisamide de récepteur éboueur bl |
| JP2016510047A (ja) * | 2013-03-05 | 2016-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｃｖ−抗ウイルス薬としてのｎ−ヘテロアリール置換アニリン誘導体 |
| TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| CN105518005B (zh) | 2013-07-02 | 2018-07-20 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| US9353078B2 (en) * | 2013-10-01 | 2016-05-31 | New York University | Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof |
| RU2676684C2 (ru) | 2014-02-20 | 2019-01-10 | ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА |
| US10329265B2 (en) | 2014-08-22 | 2019-06-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| TW201629035A (zh) * | 2014-10-06 | 2016-08-16 | 奇尼塔公司 | 抗病毒化合物、醫藥組合物及其使用方法 |
| US10584125B2 (en) | 2014-11-13 | 2020-03-10 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| EP3053920B1 (fr) * | 2015-02-05 | 2020-04-08 | AB Science | Composés présentant une activité antitumorale |
| CA2977401A1 (fr) | 2015-02-27 | 2016-09-01 | The Regents Of The University Of California | Petites molecules permettant le rajeunissement du cartilage |
| CA2981732C (fr) * | 2015-04-07 | 2024-03-12 | Boris Khalfin | Compositions de traitement et/ou de prevention de la necrose tissulaire ou cellulaire ciblant specifiquement la cathepsine c et/ou cela1 et/ou cela3a et/ou des enzymes y etant structurellement apparentees |
| EP3366691A1 (fr) | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
| CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
| ES3010661T3 (en) | 2016-02-26 | 2025-04-04 | Univ Leland Stanford Junior | Pi-kinase inhibitors with anti-infective activity |
| BR112018070602A2 (pt) | 2016-04-07 | 2019-02-05 | Glaxosmithkline Ip Dev Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio |
| EP3439656A4 (fr) | 2016-04-07 | 2020-03-11 | Duke University | Inhibiteurs doubles à petites molécules de trpv4 et trpa1 pour la désinfection et l'anesthésie |
| PL3440076T3 (pl) | 2016-04-07 | 2022-09-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocykliczne amidy przydatne jako modulatory białek |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN120887906A (zh) | 2016-05-10 | 2025-11-04 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3454856B1 (fr) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109843265A (zh) * | 2016-08-26 | 2019-06-04 | 加利福尼亚大学董事会 | 毛囊干细胞活化和毛发生长 |
| US10875861B1 (en) | 2017-05-26 | 2020-12-29 | Rutgers, The State University Of New Jersey | Therapeutic compounds |
| WO2018237026A1 (fr) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | Dégrons et dégronimères à liaison n/o pour la dégradation de protéines |
| CA3077337A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des genes (sting) de l'interferon |
| WO2019069269A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih |
| BR112020008727A2 (pt) | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
| WO2019164996A1 (fr) | 2018-02-21 | 2019-08-29 | Southern Research Institute | Analogues de 2-aminoaryl-5-aryloxazole destinés au traitement de maladies neurodégénératives |
| AU2019247766A1 (en) | 2018-04-03 | 2020-10-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US11718593B2 (en) * | 2018-05-17 | 2023-08-08 | Southern Research Institute | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| EP3886848A4 (fr) | 2018-11-27 | 2022-08-17 | Rutgers, The State University of New Jersey | Composés pharmaceutiques et méthodes thérapeutiques |
| CN114174275A (zh) | 2019-03-21 | 2022-03-11 | 小利兰·斯坦福大学托管委员会 | Pi4-激酶抑制剂及其使用方法 |
| US20220251079A1 (en) | 2019-05-16 | 2022-08-11 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| JP2022533390A (ja) | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CA3170411A1 (fr) | 2020-03-03 | 2021-09-10 | Christopher L. Vandeusen | Inhibiteurs d'eif4e et leurs utilisations |
| MA59379B1 (fr) | 2020-04-24 | 2025-04-30 | Bayer Aktiengesellschaft | Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire |
| BR112022024382A2 (pt) | 2020-05-29 | 2023-05-02 | Blueprint Medicines Corp | Formas sólidas de pralsetinibe |
| EP4392421A1 (fr) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Inhibiteurs d'eif4e et leurs utilisations |
| AU2022334296A1 (en) * | 2021-08-25 | 2024-03-07 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US12404242B2 (en) | 2021-12-17 | 2025-09-02 | Reglagene, Inc. | Compositions and methods for making and using small molecules in the treatment of cancer |
| CN114249702B (zh) * | 2022-01-12 | 2023-09-05 | 沈阳药科大学 | N-芳基-[2,4′-双噻唑]-2′-胺类化合物及其制备与用途 |
| EP4466265A1 (fr) * | 2022-01-17 | 2024-11-27 | Centre National de la Recherche Scientifique | Inhibiteurs de désoxycytidine kinase |
| CN116531373B (zh) * | 2022-01-26 | 2025-02-25 | 上海日馨医药科技股份有限公司 | 噻唑类化合物、其药物组合物及应用 |
| EP4673130A1 (fr) | 2023-02-28 | 2026-01-07 | Reglagene, Inc. | Compositions et procédés de fabrication et d'utilisation de petites molécules pour le traitement d'états pathologiques |
| WO2025151517A1 (fr) * | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Composés thiazole, compositions et méthodes de traitement de troubles associés au mauvais repliement de la protéine alpha-synucléine |
| WO2025166015A2 (fr) * | 2024-02-02 | 2025-08-07 | Photys Therapeutics, Inc. | Composés bifonctionnels de liaison à l'abl1 et leurs utilisations |
| WO2026017723A1 (fr) * | 2024-07-19 | 2026-01-22 | Givaudan Sa | Composé organique |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2474194A (en) | 1941-08-30 | 1949-06-21 | American Cyanamid Co | N-heterocyclic substituted guanamines |
| US3458526A (en) * | 1966-09-26 | 1969-07-29 | Upjohn Co | Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles |
| US3467666A (en) * | 1966-11-07 | 1969-09-16 | Geigy Chem Corp | 2-substituted aminothiazoles |
| BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
| CA1051906A (fr) | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Derives du thiazole et production dudit derive |
| DK150068C (da) | 1978-06-02 | 1987-06-29 | Pfizer | Analogifremgangsmaade til fremstilling af aminothiazoler |
| JPS6339868A (ja) | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
| DD271258A1 (de) | 1988-04-06 | 1989-08-30 | Univ Leipzig | Mittel zur chemotherapie von kulturpflanzenvirosen |
| DE4029771A1 (de) | 1990-09-20 | 1992-03-26 | Basf Ag | N-heteroaryl-2-nitroaniline |
| AU689972B2 (en) | 1994-11-29 | 1998-04-09 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| EP0871619B1 (fr) | 1995-12-29 | 2002-11-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Derives de phenylthiazole dotes de proprietes anti virus de l'herpes |
| MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| WO2000006575A2 (fr) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Plc | Nouveaux composes |
| JP2002526482A (ja) * | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| WO2000033837A2 (fr) | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | Inhibiteurs de la kinase myt1 |
| WO2001021160A2 (fr) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Derives de carboxamide, inhibiteurs selectifs d'agents pathogenes |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CA2397661C (fr) | 2000-03-01 | 2012-01-03 | Janssen Pharmaceutica N.V. | Derives de thiazolyle 2,4-disubstitue |
| AU2001249670A1 (en) | 2000-04-03 | 2001-10-15 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1 |
| WO2002030357A2 (fr) * | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Composes et procedes servant a moduler la fonction de ccr4 |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| WO2002051410A2 (fr) | 2000-12-22 | 2002-07-04 | Akzo Nobel N.V. | Derives de phenylthiazole et thiazoline et leur utilisation comme antiparasites |
| CA2436739A1 (fr) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Agent de combinaison |
| US7169931B2 (en) | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
| WO2002094264A1 (fr) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Antagonistes de ccr4 |
| HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| BR0211887A (pt) | 2001-08-13 | 2004-09-21 | Janssen Pharmaceutica Nv | Derivados de triazolil 2-amino-4,5-trissubstituìdo |
| WO2003027085A2 (fr) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20 |
| US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
| US20040267017A1 (en) | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
| US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| US20040209924A1 (en) | 2001-09-26 | 2004-10-21 | Barry Hart | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
| MXPA04003169A (es) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion. |
| US7105559B2 (en) | 2001-10-03 | 2006-09-12 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| US7163952B2 (en) | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP1467981A1 (fr) | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
| US20030158199A1 (en) | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
| US6919294B2 (en) | 2002-02-06 | 2005-07-19 | Japan Energy Corporation | Method for preparing hydrogenation purification catalyst |
| ES2294344T3 (es) | 2002-08-02 | 2008-04-01 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit. |
| RU2324685C2 (ru) * | 2002-08-07 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy |
| CA2512899A1 (fr) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme |
| MXPA05008309A (es) | 2003-02-10 | 2005-09-20 | Amgen Inc | Ligandos de receptor vaniloide y su uso en tratamientos. |
| EP2562158A1 (fr) | 2003-02-10 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Procédés pour la préparation de n-hétéroaryl-N-aryl-aminés par mise en réaction d'un ester d'acide N-aryl-carbamique avec un halo-hétéroaryle et procédés analogues |
| JP2006517577A (ja) * | 2003-02-12 | 2006-07-27 | ファイザー・インク | 抗増殖性の２−（スルホ−フェニル）−アミノチアゾール誘導体 |
| AU2004210711B2 (en) | 2003-02-12 | 2010-07-08 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| WO2004076693A1 (fr) | 2003-02-27 | 2004-09-10 | Ab Science | Traitement individualise pour differentes formes de mastocytose |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| MXPA05010967A (es) | 2003-04-15 | 2005-11-28 | Pfizer | Acidos carboxilicos alfa sustituidos como moduladores ppar. |
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| WO2004096225A2 (fr) | 2003-04-28 | 2004-11-11 | Ab Science | Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de l'ischemie cerebrale |
| WO2004098612A2 (fr) | 2003-05-07 | 2004-11-18 | Ab Science | Nouveaux analogues de calcitriol et leur utilisation |
| CA2525547C (fr) | 2003-05-14 | 2012-07-03 | Torreypines Therapeutics, Inc. | Composes et leurs utilisations pour la modulation de l'amyloide-beta |
| DE602004022668D1 (de) | 2003-06-03 | 2009-10-01 | Novartis Ag | 5-gliedrige heterocyclische p-38 inhibitoren |
| WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| DE602004013792D1 (de) | 2003-08-15 | 2008-06-26 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
| PL1670448T3 (pl) | 2003-09-30 | 2008-04-30 | Tibotec Pharm Ltd | Sulfonamidy inhibitujące HCV |
| EP1686949A2 (fr) * | 2003-11-24 | 2006-08-09 | Viropharma Incorporated | Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees |
| KR20060129413A (ko) | 2004-01-30 | 2006-12-15 | 에이비 사이언스 | 티로신 키나제 억제제로서의2-(3-치환된-아릴)아미노-4-아릴-티아졸 |
| WO2005077368A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique iii |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| CA2562242A1 (fr) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Thiazoles polycyliques utilises en tant que modulateurs du canal des ions potassium |
| EP1755592A1 (fr) | 2004-04-20 | 2007-02-28 | AB Science | Utilisation d'inhibiteurs de c-kit pour le traitement de troubles musculaires inflammatoires comprenant la myosite et la dystrophie musculaire |
| WO2005102318A1 (fr) | 2004-04-20 | 2005-11-03 | Ab Science | Utilisation d'inhibiteurs de c-kit dans le traitement des maladies liees au vih |
| JP2007533731A (ja) | 2004-04-23 | 2007-11-22 | アブ サイエンス | マラリア原虫関連の疾病を処置するためのｃ−ｋｉｔ阻害剤の使用法 |
| WO2005102326A2 (fr) | 2004-04-23 | 2005-11-03 | Ab Science | Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales |
| US20070225293A1 (en) | 2004-04-23 | 2007-09-27 | Ab Science | Use of C-Kit Inhibitors for Treating Fibrosis |
| CA2566104A1 (fr) | 2004-05-18 | 2005-12-01 | Ab Science | Utilisation d'inhibiteurs de mastocytes dans le traitement de patients exposes a des armes chimiques ou biologiques |
| WO2005115385A1 (fr) | 2004-05-24 | 2005-12-08 | Ab Science | Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne |
| WO2005115304A2 (fr) | 2004-05-24 | 2005-12-08 | Ab Science | Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie |
| BRPI0515571A (pt) | 2004-09-23 | 2008-07-29 | Pfizer Prod Inc | agonistas de receptor de trombopoetina |
| CN101248052A (zh) | 2005-05-11 | 2008-08-20 | 艾博特公司 | 香草素受体亚型1(vr1)拮抗剂及其用途 |
| WO2007095603A2 (fr) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique |
| JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
| WO2008147557A2 (fr) * | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Thiazoles à substitution hétéroaryle |
-
2006
- 2006-05-09 EP EP06770077A patent/EP1879575A2/fr not_active Withdrawn
- 2006-05-09 SG SG201001098-1A patent/SG159561A1/en unknown
- 2006-05-09 KR KR1020077028496A patent/KR20080019213A/ko not_active Ceased
- 2006-05-09 CA CA002607617A patent/CA2607617A1/fr not_active Abandoned
- 2006-05-09 CN CNA200680025066XA patent/CN101247807A/zh active Pending
- 2006-05-09 MX MX2007013955A patent/MX2007013955A/es not_active Application Discontinuation
- 2006-05-09 US US11/431,155 patent/US8088806B2/en not_active Expired - Fee Related
- 2006-05-09 AP AP2007004268A patent/AP2358A/xx active
- 2006-05-09 AU AU2006244203A patent/AU2006244203B2/en not_active Ceased
- 2006-05-09 UA UAA200713741A patent/UA92746C2/ru unknown
- 2006-05-09 NZ NZ563866A patent/NZ563866A/en not_active IP Right Cessation
- 2006-05-09 EA EA200702445A patent/EA200702445A1/ru unknown
- 2006-05-09 JP JP2008511226A patent/JP2008540537A/ja active Pending
- 2006-05-09 WO PCT/US2006/017692 patent/WO2006122011A2/fr not_active Ceased
- 2006-05-09 BR BRPI0608910-0A patent/BRPI0608910A2/pt not_active IP Right Cessation
-
2007
- 2007-10-28 IL IL186970A patent/IL186970A0/en unknown
- 2007-11-09 NO NO20075723A patent/NO20075723L/no not_active Application Discontinuation
- 2007-11-13 ZA ZA200709751A patent/ZA200709751B/xx unknown
-
2011
- 2011-11-30 US US13/307,761 patent/US20120108576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006122011A2 (fr) | 2006-11-16 |
| MX2007013955A (es) | 2008-02-05 |
| US20070004711A1 (en) | 2007-01-04 |
| UA92746C2 (en) | 2010-12-10 |
| EA200702445A1 (ru) | 2008-04-28 |
| AU2006244203A1 (en) | 2006-11-16 |
| AP2358A (en) | 2012-01-30 |
| IL186970A0 (en) | 2008-02-09 |
| KR20080019213A (ko) | 2008-03-03 |
| ZA200709751B (en) | 2008-11-26 |
| EP1879575A2 (fr) | 2008-01-23 |
| AP2007004268A0 (en) | 2007-12-31 |
| US20120108576A1 (en) | 2012-05-03 |
| US8088806B2 (en) | 2012-01-03 |
| JP2008540537A (ja) | 2008-11-20 |
| AU2006244203B2 (en) | 2012-05-03 |
| BRPI0608910A2 (pt) | 2010-02-17 |
| WO2006122011A3 (fr) | 2007-05-03 |
| NZ563866A (en) | 2011-03-31 |
| SG159561A1 (en) | 2010-03-30 |
| CA2607617A1 (fr) | 2006-11-16 |
| CN101247807A (zh) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075723L (no) | Tiazolforbindelser og fremgangsmater for anvendelse | |
| NO20065736L (no) | Substituerte arylacyltioureaer og relaterte forbindelser; Inhibitorer av viral reproduksjon | |
| NO20052546L (no) | Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon. | |
| NO20062928L (no) | Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon | |
| MX2010006209A (es) | Derivados de quinoxalinilo. | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| DK1615613T3 (da) | Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer | |
| NO20062101L (no) | Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease | |
| MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| WO2009053828A3 (fr) | Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c | |
| MX2010010276A (es) | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| WO2008002924A3 (fr) | Inhibiteurs macrocycliques quinoxalinyliques des protéases à sérine du virus de l'hépatite c | |
| EA200500610A1 (ru) | Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae | |
| WO2005077969A3 (fr) | Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a | |
| MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
| WO2008022006A3 (fr) | Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle | |
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| CY1117576T1 (el) | Δινουκλεοτιδικα προφαρμακα | |
| WO2008021871A3 (fr) | Inhibiteurs triazolyle acyclique de la sérine protéase de l'hépatite c | |
| WO2009076166A3 (fr) | Inhibiteurs oximyles de la sérine protéase de vhc | |
| WO2008021960A3 (fr) | Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c | |
| MX2010008109A (es) | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). | |
| TH82492A (th) | ซับสทิทิวเทด แอริล แอซิลไธ โอยูเรียและสารประกอบที่เกี่ยวข้อง; ตัวยับยั้งการถ่ายแบบไวรัส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |